Menopausal symptom burden and quality of life in women with breast cancer on endocrine adjuvant therapy: findings from the REALISE study

Background: Women receiving endocrine adjuvant (EA) therapy after breast cancer treatment report high rates of menopausal symptoms including vasomotor symptoms (VMS). VMS impact quality of life and can lead to treatment discontinuation and reduced survival, but existing literature evaluating symptom burden and impact is limited. The REAL-world evIdence on vasomotor and other Symptoms in menopausal womEn (REALISE) study aimed to evaluate physician and patient perceptions of symptom burden and impact in women experiencing VMS while receiving EA therapy for breast cancer.